Burkitt Lymphoma International Prognostic Index.

ABSTRACT:

Purpose

Burkitt lymphoma (BL) has unique biology and clinical course but lacks a standardized prognostic model. We developed and validated a novel prognostic index specific for BL to aid risk stratification, interpretation of clinical trials, and targeted development of novel treatment approaches.

Methods

We derived the BL International Prognostic Index (BL-IPI) from a real-world data set of adult patients with BL treated with immunochemotherapy in the United States between 2009 and 2018, identifying candidate variables that showed the strongest prognostic association with progression-free survival (PFS). The index was validated in an external data set of patients treated in Europe, Canada, and Australia between 2004 and 2019.

Results

In the derivation cohort of 633 p

SUBMITTER: Olszewski AJ 

PROVIDER: S-EPMC9851706 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature